Akorn, Inc. Names Marshall L. Goodwin as Vice President, Global Quality and Regulatory Compliance.

BUFFALO GROVE, Ill. -- Akorn, Inc. (OTCBB:AKRN.OB) today announced the appointment of Marshall L. Goodwin as Vice President, Global Quality and Regulatory Compliance. Mr. Goodwin has over twenty-five years of quality assurance and operations management experience in pharmaceuticals and medical devices.

Before joining Akorn, Mr. Goodwin served at Hospira, Inc. as Director, Quality Assurance Operations, Parenteral Drug Manufacturing, where he directed the total quality systems operations at four manufacturing plants. Hospira Inc. is a specialty pharmaceuticals and medication delivery company and was spun off from Abbott Laboratories, Inc in May 2004. Mr. Goodwin held the same position with Abbott from 2000 until the spin-off.

Beginning in 1982, Mr. Goodwin served in progressively responsible roles with Abbott. Prior to his most recent assignment, he served as General Manager at Abbott's Ambulatory Infusion Systems facility in San Diego, CA, (1998-2000), Director, Quality Assurance Operations, Critical Care Products, Morgan Hill, CA (1996-1998), and Site Quality Assurance Manager, Mountain View, CA. Prior to these assignments, he held key quality and manufacturing management positions with Abbott at their facilities in the Dominican Republic, Puerto Rico and Austin, TX. Mr. Goodwin received a BS in Chemistry and a BA in Microbiology from Texas Tech University.

Arthur S. Przybyl, president and chief executive officer, stated, "We are excited to have Marshall join our senior management team. Marshall brings nearly thirty years of specialty pharmaceuticals experience to Akorn and we are confident that his quality assurance, regulatory and manufacturing expertise will be a great asset to Akorn."

About Akorn, Inc.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company's website at www.akorn.com.

Any statements made by Akorn, Inc. ("we", "us", "our", "Akorn" or the "Company") in this press release that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The company cautions readers that important factors may affect the Company's actual results and could cause such results to differ materially from forward-looking statements made by or on behalf of the Company. Such factors include, but are not limited to, risks and uncertainties relating to (i) the ability to generate cash from operations sufficient to meet the Company's working capital requirements, (ii) the necessity of complying with various regulatory procedures in the manufacture of drug products, (iii) the Company's ability to acquire, develop, finance, test, produce and market new products, including the availability of materials to produce products, (iv) the resolution of the FDA compliance issues at the Company's Decatur, Illinois manufacturing facility and the outcome of other legal proceedings involving the Company, (v) patent protection for the Company's intellectual property or trade secrets, and (vi) other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including, but not limited to, those risks referenced under the caption "Factors That May Affect Future Results" in Item 1 of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2003.